

## **Azure Health Technology Limited completes first manufacturing run in the US for nutraceutical products.**

**Sydney, Australia, 16 March 2021** – Azure Health Technology Limited (AZT) today announced that it has completed manufacturing the first batch of nutraceutical products in the US for sale in the US, Australia and China.

AZT's wholly owned subsidiaries, Invictus BioPharma Pty Ltd (based in Melbourne, Australia) and Invictus Nutraceuticals, Inc. (IVN) (based in Florida, USA) have been working closely with a leading cGMP (current Good Manufacturing Practice) and TGA (Therapeutic Goods Administration (TGA) approved manufacturer in the US since 2018 to develop optimum formulations for AZT's proprietary and patented nutraceutical products, NE1-Elite® and NE1-Heart®. Both products are based on annatto-derived delta tocotrienols delivered using AZT's MELT3® (Melt then Swallow) platform. NE1-Elite® has been clinically-proven to reduce Delayed Onset Muscle Soreness (DOMS), improve muscle recovery after exercise and improve maintenance of peak muscle power. NE1-Heart® acts as a strong antioxidant in the body and maintains heart health.

IVN's President and Chief Executive Officer, Richard Estalella said "The feedback that we have received from people who have tried NE1-Elite® has been unanimously positive and surprising in a very good way. We have had reports from a range of sportspeople including champion marathon runners, (grid-iron) football players and long-distance bike riders and they all say that NE1-Elite® has completely transformed the way that they enjoy their sports and has allowed them to play harder for longer and recover quicker. These real life results are totally consistent with the clinical data that we have gathered to date".

A pilot-scale manufacturing run of samples of both products was completed in October 2018. The formulations and methodologies developed in conjunction with the cGMP manufacturer in the US were assessed to be suitable for commercial-scale cGMP manufacturing. Since that time, IVN has engaged with prospective distributors, strategic partners and consumers to thoroughly assess the market in the US, Australia and China. The feedback received has been overwhelmingly positive and very encouraging. Moreover, both products are now ready for sale in the US and are listed on Australia's Therapeutic Goods Administration's (TGA's) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines.

AZT's CEO and Managing Director, Dr Glenn Tong, said "Having the first finished products ready for sale in a major market like the US is a huge milestone for AZT. We started with simply a concept nine years ago which we have now taken through the various stages of intellectual property protection, product development, and clinical development. Now we are extremely excited to see the products coming off the manufacturing line and ready to sell to consumers".

AZT is at the present time conducting a capital raising via an Initial Public Offer (IPO) and listing on the National Stock Exchange (NSX). For Australian investors who are interested in finding out more information about AZT's IPO, the Prospectus can be accessed at: <https://www.azureht.com.au/>

For more information please contact:

**Dr. Glenn Tong**, CEO and Managing Director  
Ph: +61 (0) 412 193 350

**Catriona Glover**, Company Secretary  
Tel: +61 (0) 402 328 200

---

### **About Azure Health Technology Limited**

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.azureht.com.au>